Novo Nordisk hands a Parkinson’s cell therapy to Cellular Intelligence, a startup trying to design cell behavior

Cellular Intelligence has acquired global rights to a clinical-stage Parkinson’s cell therapy, from Novo Nordisk, which took an equity stake in the startup and retained milestone and royalty rights. Cellular Intelligence, formerly Somite AI, has raised over $60 million from Khosla Ventures, AMD Ventures, CZI, SciFi VC and others to build foundation models that predict… The post Novo Nordisk hands a Parkinson’s cell therapy to Cellular Intelligence, a startup trying to design cell behavior appeared first on Drug Discovery and Development.

Continue reading →